After writing dozens of GLP-1 articles over the past year, one issue that consistently comes up is the affordability of ...

Hims & Hers Health, Inc. could see more upside in partnerships and international expansion. Click here to read an analysis of ...

Novo Nordisk NVO is a dominant player in the cardiometabolic space, which markets its blockbuster semaglutide-based (GLP-1) ...

How long would you need to jab yourself...and contend with the cost? Two MDs specializing in weight loss and endocrinology share how it works.

Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.

Direct-to-consumer (DTC) telehealth companies remove barriers to care, but questions remain regarding patient safety and proper information.

Hosts David and Gina explore the unexpected origins of blockbuster diabetes and weight-loss drugs like Ozempic and Wegovy ...

Investors got to hear Novo Nordisk’s side of the Metsera bidding war drama for the first time on Wednesday, as the company ...

New clinician-guided program blends medical science, microdosing, and 24/7 support to make advanced weight loss and wellness ...

In a world where stigma around weight is still prevalent, I believe that treating obesity as a chronic disease is essential ...

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

Despite no strong evidence of clinical benefit, microdosing GLP-1s will likely continue as a strategy for some to profit off ...